

AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, including listings, of claims in the application.

Claims 1-11 (Canceled).

Claim 12 (Previously Presented): The compound according to claim 46, wherein -A is an -OR₁ type radical.

Claim 13 (Currently Amended): [[The]] A compound ~~according to claim 46~~ selected from the group consisting of:

(2S)-3-(4-benzyloxyphenyl)-2-[4-(4-butoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(3-bromobenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-fluorobenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(3-methylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid methyl ester;

Application Serial No. 10/560,533
Amendment dated 10 August 2010
Reply to Office Action dated 2 June 2010

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-*o*-tolylethoxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-{4-[3-(4-propoxymethoxy)propoxy]benzoylamino}propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(3-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-ethoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(4-butylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-2-[4-(4-butylbenzyloxy)benzoylamino]-3-cyclohexylpropionic acid methyl ester;

(2S)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}-3-phenylpropionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-pyridin-2-ylethoxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(pyridin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-8-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-7-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

Application Serial No. 10/560,533
Amendment dated 10 August 2010
Reply to Office Action dated 2 June 2010

(2S)-3-(4-benzyloxyphenyl)-2-{4-[3-(3-methylquinoxalin-2-yloxy)propoxy]benzoylamino}propionic acid methyl ester;
(2S)-3-(4-bromophenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2S)-3-(4-fluorophenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid ethyl ester;
(2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid isopropyl ester;
(2S)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid propyl ester;
(2S)-2-(4-benzyloxybenzoylamino)-3-(4-benzyloxyphenyl)propionic acid;
(2S)-2-[4-(3-benzyloxybenzyl)oxy]benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
3-[(3-benzyloxybenzyl)-[4-(2-dibenzylaminoethoxy)benzoyl]amino}propionic acid;
3-((3-benzyloxybenzyl)-{3-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoyl}amino)propionic acid;


Application Serial No. 10/560,533
Amendment dated 10 August 2010
Reply to Office Action dated 2 June 2010

3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid;
and
3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid.

Claim 14 (Previously Presented): A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of the compound according to claim 46 together with appropriate amounts of pharmaceutically acceptable excipients.

Claims 15-45 (Canceled).

Claim 46 (Previously Presented): A compound of formula (I),



(I)

its stereoisomers and mixtures thereof, and addition salts of all of them, wherein the central benzene ring may be substituted in *meta*- or *para*- position and,

- A is a radical selected from the group consisting of -OR1, -NR2OR1 and -NR2R3; wherein R1, R2 and R3 independently represent -H or -(C₁-C₄)-alkyl;
- W- is a biradical -NH-CH(E)-, wherein E is a radical of the -G-I-J-K type where:
- G- is a bond or a -(CH₂)₁₋₄- biradical;

-I- is a biradical of a cycle selected from the following groups:

- a) cyclohexane optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and
- b) benzene substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-J- is a bond or a biradical selected from the following groups:

- a) -(CH₂)₁₋₄-alkylidene;
- b) -O- and
- c) -O-(C₁-C₄)- alkyl-;

-K- is a radical selected from the following groups:

- a) -H;
- b) (C₁-C₄)-alkyl; and
- c) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-Z- is a radical of -Q-I'-J-T wherein

-Q- is a biradical -(CH₂)₁₋₃-;

-I'- is benzene optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by

one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-J- is as defined above; and

-T is a radical selected from the following groups:

- a.a) -H;
- a.b) (C₁-C₄)-alkyl;
- a.c) a radical from a five- or six-membered heterocycle containing from one to two heteroatoms selected from O, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and
- a.d) phenyl or a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to two heteroatoms selected from O, S and N, the phenyl or the bicyclic system being optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

with the proviso that compound of formula (I) is neither of:

- 2-(4-benzyloxybenzoylamino)-3-phenylpropionic acid,
- 2-[4-(4-methoxybenzyloxy)benzoylamino]-3-phenylpropionic acid,
- 2-[4-(4-bromobenzyloxy)benzoylamino]-3-phenylpropionic acid,
- 2-(4-benzyloxybenzoylamino)-3-biphenyl-4-ylpropionic acid or
- 2-(4-benzyloxybenzoylamino)-3-(4'-trifluoromethoxybiphenyl-4-yl)propionic acid.

Application Serial No. 10/560,533
Amendment dated 10 August 2010
Reply to Office Action dated 2 June 2010

Claim 47 (new): A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of the compound according to claim 13 together with appropriate amounts of pharmaceutically acceptable excipients.